Press Release Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 3
Press Release Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 Aug 3
Press Release Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston Jul 29